Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis
- PMID: 20498206
- PMCID: PMC2938882
- DOI: 10.1136/ard.2009.121871
Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis
Abstract
Subjects: with rheumatoid factor positive inflammatory polyarthritis (IP) are known to have increased mortality from cardiovascular disease (CVD). A study was undertaken to examine the risk and baseline predictors of admission with CVD in patients with recent-onset IP.
Methods: Subjects are recruited by the Norfolk Arthritis Register if they present to primary or secondary care with > or =2 swollen joints lasting > or =4 weeks. This analysis includes subjects recruited between 1995 and 1999. Baseline data on lifestyle, demographic characteristics, disease and treatment characteristics were collected. CVD admissions were identified through record linkage with the only acute care hospital in the study region. First-episode hospitalisation rates were compared with those of the general population. Poisson regression was used to calculate the relative risk (RR) of admission for patients with IP (overall and for each risk factor). Death certificates were obtained from the national death register.
Results: 800 patients with recent-onset IP were followed for a median of 7.0 years. 64 CVD-related hospitalisations were observed (11.7 per 1000 person-years). Patients with IP were twice as likely (RR=2.0; 95% CI 1.5 to 2.5) to be hospitalised for CVD as the general population. Difficulty walking at baseline was a significant predictor of CVD admission and baseline non-steroidal anti-inflammatory drug use was associated with a reduced risk of CVD admission.
Conclusions: Patients with IP are at increased risk of CVD-related hospitalisation, within 7 years of symptom onset. Informing patients about lifestyle modification may reduce the risk of CVD.
Conflict of interest statement
Similar articles
-
Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.Ann Rheum Dis. 2009 Mar;68(3):367-72. doi: 10.1136/ard.2007.076760. Epub 2008 Apr 13. Ann Rheum Dis. 2009. PMID: 18408253 Free PMC article.
-
N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR).Ann Rheum Dis. 2014 Apr;73(4):684-90. doi: 10.1136/annrheumdis-2012-202848. Epub 2013 Mar 19. Ann Rheum Dis. 2014. PMID: 23511225 Free PMC article.
-
Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register.Ann Rheum Dis. 2007 Apr;66(4):486-92. doi: 10.1136/ard.2006.056390. Epub 2006 Nov 7. Ann Rheum Dis. 2007. PMID: 17090565 Free PMC article.
-
Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis.Ann Rheum Dis. 2006 May;65(5):617-22. doi: 10.1136/ard.2005.044784. Epub 2005 Oct 25. Ann Rheum Dis. 2006. PMID: 16249224 Free PMC article. Review.
-
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Ann Rheum Dis. 2017. PMID: 27697765 Review.
Cited by
-
The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study.Arthritis Res Ther. 2012 Nov 28;14(6):R258. doi: 10.1186/ar4103. Arthritis Res Ther. 2012. PMID: 23190682 Free PMC article.
-
Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy.Rheumatol Int. 2018 Feb;38(2):211-217. doi: 10.1007/s00296-017-3860-9. Epub 2017 Oct 27. Rheumatol Int. 2018. PMID: 29079928
-
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.Ther Adv Musculoskelet Dis. 2013 Aug;5(4):166-81. doi: 10.1177/1759720X13491025. Ther Adv Musculoskelet Dis. 2013. PMID: 23904862 Free PMC article.
-
Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment.Ann Rheum Dis. 2011 May;70(5):719-21. doi: 10.1136/ard.2010.145482. Epub 2011 Feb 22. Ann Rheum Dis. 2011. PMID: 21345812 Free PMC article. No abstract available.
-
We should not avoid diclofenac in the treatment of spondyloarthritis.Ann Transl Med. 2018 Nov;6(Suppl 1):S36. doi: 10.21037/atm.2018.09.42. Ann Transl Med. 2018. PMID: 30613611 Free PMC article. No abstract available.
References
-
- Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010–19 - PubMed
-
- Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7 - PubMed
-
- Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475–9 - PubMed
-
- Symmons DP, Silman AJ. The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol 2003;21(5 Suppl 31):S94–9 - PubMed